Immunovant Q3 net loss smaller than expected

Immunovant

06/02/2026 12:08

Overview

Clinical-stage immunology firm's Q3 net loss beat analyst expectations

Company completed $550 mln financing, extending cash runway for IMVT-1402 launch

R&D expenses rose due to IMVT-1402 clinical trial activities

Outlook

Immunovant expects topline data for IMVT-1402 trials in 2026 and 2027

Company anticipates batoclimab Phase 3 data in first half of 2026

Immunovant extends cash runway to support IMVT-1402 launch in Graves’ disease

Result Drivers

R&D EXPENSES - Increase in R&D expenses primarily due to IMVT-1402 clinical trials and contract manufacturing costs

FINANCING - $550 mln financing completed, extending cash runway for IMVT-1402 launch

CLINICAL TRIAL PROGRESS - IMVT-1402 trials across multiple indications remain on track

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
Beat
-$110.64 mln
-$125.06 mln (12 Analysts)
Q3 Basic EPS
-$0.61
Q3 Operating Expenses
$114.36 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Immunovant Inc is $44.00, about 82.9% above its February 5 closing price of $24.06

Press Release: ID:nGNX39KTkZ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)